NCT06637254View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

219

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

March 22, 2026

Study Completion Date

September 20, 2026

Conditions

Bronchial Asthma

Interventions

DRUG

HSK31858

HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma

DRUG

Placebo

the placebo comparator of study

Trial Locations (1)

200000

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY